Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-HBs Seroconversion Following Withdrawal of Anti-HBV-Active Agents: An Underrecognized Form of HBV Reactivation?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Molecular epidemiology of Treponema pallidum subsp. pallidum among men who have sex with men at an HIV referral hospital in Tokyo: Multilocus sequence typing and macrolide resistance.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Treatment failure with bictegravir/emtricitabine/tenofovir alafenamide in a treatment-naïve person with HIV under perfect adherence.

Internal medicine (Tokyo, Japan)·2026
Same author

From Diagnostic Challenge to Clinical Success: Rapid Multiplex PCR Identification of Cryptosporidium in HIV-Associated Refractory Diarrhea: A Case Report.

Clinical case reports·2026
Same author

Dysfunction of circulating follicular helper T cells in people living with HIV who are HBV small surface protein antibody (HBsAb)-negative despite HBV vaccination.

BMC infectious diseases·2026
Same author

Genomic Landscape and Therapeutic Implications of Metaplastic Breast Carcinoma: Insights from a Nationwide Database Including Diagnostic Mimickers.

Pharmaceuticals (Basel, Switzerland)·2026

Related Experiment Video

Updated: May 21, 2026

Intravital Microscopy Imaging of the Liver following Leishmania Infection: An Assessment of Hepatic Hemodynamics
10:48

Intravital Microscopy Imaging of the Liver following Leishmania Infection: An Assessment of Hepatic Hemodynamics

Published on: July 28, 2015

Liver dysfunction in patients with early syphilis: a retrospective study.

Eisuke Adachi1, Tomohiko Koibuchi, Michio Okame

  • 1Department of Infectious Diseases and Applied Immunology, Research Hospital of the Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
|June 14, 2012
PubMed
Summary

Syphilis can cause liver problems. A study found 39% of early syphilis patients had liver enzyme abnormalities, with 2.7% diagnosed with syphilitic hepatitis, highlighting its importance in differential diagnosis.

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Related Experiment Videos

Last Updated: May 21, 2026

Intravital Microscopy Imaging of the Liver following Leishmania Infection: An Assessment of Hepatic Hemodynamics
10:48

Intravital Microscopy Imaging of the Liver following Leishmania Infection: An Assessment of Hepatic Hemodynamics

Published on: July 28, 2015

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Sexually Transmitted Infections

Background:

  • Liver dysfunction is a recognized complication of various infections.
  • Syphilis, caused by *Treponema pallidum*, is a complex systemic infection.
  • Syphilitic hepatitis is an uncommon but documented manifestation of secondary syphilis.

Purpose of the Study:

  • To investigate the incidence of liver enzyme abnormalities in patients diagnosed with early syphilis.
  • To determine the prevalence of syphilitic hepatitis as a cause of liver dysfunction in this population.

Main Methods:

  • Retrospective study design.
  • Analysis of liver function tests in patients with confirmed early syphilis.
  • Identification of cases diagnosed with syphilitic hepatitis.

Main Results:

  • 39% (44/112) of patients with early syphilis exhibited liver enzyme abnormalities at diagnosis.
  • 2.7% (3/112) of patients were diagnosed with syphilitic hepatitis.
  • Liver enzyme abnormalities were observed in a significant proportion of early syphilis cases.

Conclusions:

  • Syphilitic hepatitis should be considered in the differential diagnosis of liver dysfunction, particularly in patients with sexually transmitted diseases.
  • Early syphilis is an important, often overlooked, cause of hepatitis.
  • Clinicians should maintain a high index of suspicion for syphilitic hepatitis in at-risk populations.